{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.943","upperLimit":"8.378","value":"5.78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Overall survival was defined as date of first dose until death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMGN632 via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Total R/R BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg"}],"paramType":"MEDIAN","populationDescription":"mITT Population included all participants who were eligible based on the screening criteria and who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = Total R/R BPDCN participants. Per protocol, this endpoint evaluated only total R/R BPDCN participants, all of whom were in arm Schedule A: IMGN632 0.045 mg/kg.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Overall Survival in Total R/R BPDCN Participants","type":"SECONDARY","unitOfMeasure":"months"}